1. ScholarBank@NUS

Wee Joo Chng

rp04705

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
Wee Joo Chng
Variants
Chng W.J
Chng, W.J.
Chng W.-J.
Wee Joo Chng
Chng, W.-J.
 
Main Affiliation
 
Faculty
 
Email
mdccwj@nus.edu.sg
 
Other emails
 

Publications

Refined By:
Department:  OFFICE OF THE DEPUTY PRESIDENT(RES&TECH)
Type:  Review
Policy:  Open

Results 1-20 of 35 (Search time: 0.022 seconds).

Issue DateTitleAuthor(s)
123-Feb-2021Application of Advanced Mass Spectrometry-Based Proteomics to Study Hypoxia Driven Cancer ProgressionVinaiphat, Arada; Low, Jee Keem; Yeoh, Kheng Wei ; Chng, Wee Joo ; Sze, Siu Kwan
21-Mar-2022Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaZhou, Jianbiao ; Chng, Wee-Joo 
329-Apr-2021CAR T-cell therapy in multiple myeloma: more room for improvementTeoh, Phaik Ju ; Chng, Wee Joo 
41-Nov-2019Comprehensive Analysis of ERK1/2 Substrates for Potential Combination ImmunotherapiesYang, Lei ; Zheng, Liangzhen; Chng, Wee Joo ; Ding, Jeak Ling 
52020Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaDimopoulos, M.A.; Jakubowiak, A.J.; McCarthy, P.L.; Orlowski, R.Z.; Attal, M.; Bladé, J.; Goldschmidt, H.; Weisel, K.C.; Ramasamy, K.; Zweegman, S.; Spencer, A.; Huang, J.S.Y.; Lu, J.; Sunami, K.; Iida, S.; Chng, W.-J. ; Holstein, S.A.; Rocci, A.; Skacel, T.; Labotka, R.; Palumbo, A.; Anderson, K.C.
62019EZH2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implicationsLi, B. ; Chng, W.-J. 
725-May-2022Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic ChallengesDa, Yi; Goh, Giap Hean; Lau, Titus; Chng, Wee Joo ; Soekojo, Cinnie Yentia
89-Jun-2022Immunoglobulin M Monoclonal Gammopathies of Clinical SignificanceGirard, Louis-Pierre; Soekojo, Cinnie Yentia; Ooi, Melissa; Chng, Wee Joo ; de Mel, Sanjay
92020Immunoglobulin m paraproteinaemiasGirard, L.-P.; Soekojo, C.Y.; Ooi, M.; Poon, L.M.; Chng, W.-J. ; de Mel, S.
101-Mar-2020Immunotherapy in Multiple MyelomaSoekojo, Cinnie Yentia; Ooi, Melissa ; de Mel, Sanjay; Chng, Wee Joo 
112014Implications of heterogeneity in multiple myelomaDe Mel S.; Lim S.H.; Tung M.L.; Chng W.-J. 
121-Oct-2021Janus Kinase Signaling: Oncogenic Criminal of Lymphoid CancersLi, Boheng; Wan, Qin; Li, Zhubo; Chng, Wee-Joo 
131-Apr-2022Metabolic Vulnerabilities in Multiple MyelomaLim, Julia SL ; Chong, Phyllis SY ; Chng, Wee-Joo 
142014MicroRNA: Important player in the pathobiology of multiple myelomaBi C.; Chng W.J. 
152011miRNA deregulation in multiple myelomaBi C.L.; Chng W.J. 
162014MMSET: Role and therapeutic opportunities in multiple myelomaXie Z.; Chng W.J. 
171-Sep-2022Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological MalignanciesMustafa, Nurulhuda ; Azaman, Muhamad Irfan ; Ng, Giselle GK; Chng, Wee Joo 
182-Apr-2019Molecular pathogenic pathways in extranodal NK/T cell lymphomade Mel, Sanjay; Hue, Susan Swee-Shan; Jeyasekharan, Anand D ; Chng, Wee-Joo ; Ng, Siok-Bian 
192014P53 abnormalities and potential therapeutic targeting in multiple myelomaTeoh P.J.; Chng W.J. 
202018Potential clinical application of genomics in multiple myelomaSoekojo, C.Y; de Mel, S; Ooi, M ; Yan, B; Chng, W.J